Thermeutics is developing Stasis, an implantable system for cytostatic hypothermia that halts glioblastoma by cooling resection margins.

Market Opportunity:

Glioblastoma is the deadliest brain cancer, with median survival around 15 months. More than 80% of tumors return within a couple of centimeters of where they were removed. About 13,000 Americans are diagnosed each year and 300,000 people worldwide. At a modeled $50,000 per patient, the U.S. opportunity alone tops $1 billion a year, with later expansion into stroke, epilepsy, and brain injury.

Technology:

Most therapies try to kill tumor cells, which also harms nearby brain. Stasis instead cools the cavity margins to room temperature, a ‘cytostatic’ range that stops glioblastoma cells from dividing while healthy brain tolerates it. A device with a microwire array (NeuraTEC) draws heat from the margin, and a small implant under the skin (ARC) dissipates it away through a sealed fluid loop. It is placed during the same surgery that removes the tumor and runs continuously, out of sight, alongside standard care.

Advantages:

  • Stops growth without killing
  • Fully implanted and discreet
  • Continuous cooling at the margin
  • Works with standard therapy
  • Supported by survival data

Development Stage:

  • Pre-clinical: Functional prototypes have been tested in rodent survival studies and in awake pig studies. GLP safety testing and FDA pre-submission work are underway as we prepare for a first-in-human trial.

IP Protection:

Rights come from two licensed/optioned patent families, supported by additional provisional filings. The portfolio includes more than the two published applications listed below.

  • “Devices, Systems, and Methods for Modulating Tissue Temperature.” U.S. Pub. No. 2022/0378608 A1 (PCT WO 2021/076962 A1). Filed October 16, 2020. Duke University.
  • “Heat Transfer-Based Medical Treatment Systems and Methods.” PCT Pub. No. WO 2024/243564 A2. U.S. national stage entered November 24, 2025. UT Southwestern.

Select Press Releases/Publications/Presentations:

  • Enam SF, et al. Cytostatic hypothermia and its impact on glioblastoma and survival. Science Advances. 2022;8:eabq4882. https://www.science.org/doi/10.1126/sciadv.abq4882
  • Enam SF, et al. Finite-element analysis of a cytostatic-hypothermia neural implant and its heat management. Journal of Neural Engineering. 2025;22:066005.
  • Ganesan, Enam, Jain. Thermal characterization of microwires for neural cooling implants. International Journal of Thermal Sciences. 2026;220:110246.

Contact:

Website: thermeutics.com

Email: faaiz@thermeutics.com

LinkedIn: linkedin.com/company/thermeutics

Portfolio Companies